Filter By “Blog”

Privacy-preserving record linkage tools create data silos when linking patient registries. Learn which PII to collect for token creation, how to choose platforms that enable linkage, and how to update IRB protocol language.

This year, a study of ten million people revealed the power of longitudinal research. A team mined a vast medical database of US military personnel, including tissue samples and health records collected over 20 years.

Piecing together a comprehensive and accurate view of the patient journey – for example, obtaining a complete prescription history or linking clinical trial data with future healthcare encounters –  is critical to ultimately improving patient outcomes.

This summer, Datavant convened an inaugural Product Council – composed of thought leaders and health data super users within our partner ecosystem – to discuss the biggest challenges in health data exchange. This article highlights key insights from those conversations and shares ideas about how we can work together to solve those challenges.

Pete McCabe (CEO, Datavant) shares his key takeaways and insights from our 3rd annual Future of Health Data Summit. Read about industry innovation and momentum around patient centricity, interoperability, genomics data in precision medicine, and more.

While smaller datasets require care and an understanding of the privacy principles at play, we must be able to share information collected from smaller population groups in order to inform research in genetic sequencing, drug development, and medicine more broadly. Learn about the opportunities with small patient populations and the privacy considerations and mechanisms necessary to utilize their health data.

In Part 1 of this article, we discussed the evolving scientific landscape of disclosure risk in genetics data. In Part 2, we explore the legislative outcomes of this development. In particular, we will analyze the requirements of the HIPAA Omnibus Rule (2013) and propose a framework for how privacy experts should apply these in practice.

The modern landscape of health and clinical information has experienced some tectonic shifts in the quarter century since HIPAA was established. For experts in disclosure risk analysis, the challenge of balancing patient privacy, data utility, and emerging innovation is at its most vigorous - yet also its subtlest - when faced with the advent of genetic and genomic data in healthcare.

Over the last three years, the proliferation of real-world data at scale has dramatically changed how researchers are thinking about study design, operations, and execution – and the role digital patient data can play. We believe that over the next five years, tokenized clinical trials will be critical to reducing study costs and a force multiplier for accelerating therapeutic innovations for patients. Read this blog post to learn more about about vision and investment in trial tokenization.